CelgeneBUE:CELG 10 Piotroski F-Score is 8 as of Jul. 08, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.
Good Sign:
Piotroski F-Score is 8, indicating very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Celgene has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Celgene's Piotroski F-Score or its related term are showing as below:
BUE:CELG'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 5 Max: 9
Current: 8
During the past 13 years, the highest Piotroski F-Score of Celgene was 9. The lowest was 1. And the median was 5.
Celgene (BUE:CELG) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Celgene Piotroski F-Score Related Terms
Celgene Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Celgene's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: Piotroski F-Score Comparison
For the Drug Manufacturers - General subindustry, Celgene's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Celgene's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep19) TTM:
Last Year (Sep18) TTM:
Net Income was 40457.467 + 60394.05 + 70190.711 + 94570.865 = ARS265,613.09 Mil. Cash Flow from Operations was 88342.82 + 57696.84 + 96819.395 + 121471.27 = ARS364,330.33 Mil. Revenue was 152215.093 + 157337.25 + 196587.605 + 252785.516 = ARS758,925.46 Mil. Gross Profit was 145842.948 + 151864.65 + 189841.075 + 243445.874 = ARS730,994.55 Mil.
Average Total Assets from the begining of this year (Sep18)
to the end of this year (Sep19) was
(1259077.784 + 1337773.469 + 1471308.509 + 1750657.298 + 2313267.102) / 5 = ARS1626416.8324 Mil. Total Assets at the begining of this year (Sep18) was ARS1,259,077.78 Mil. Long-Term Debt & Capital Lease Obligation was ARS1,022,830.60 Mil. Total Current Assets was ARS808,354.39 Mil. Total Current Liabilities was ARS280,133.33 Mil.
Net Income was -1546.695 + 17046.054 + 26062.301 + 39816.518 = ARS81,378.18 Mil.
Revenue was 66507.882 + 71287.162 + 95121.164 + 143221.708 = ARS376,137.92 Mil. Gross Profit was 64235.577 + 68567.047 + 91978.724 + 137444.265 = ARS362,225.61 Mil.
Average Total Assets from the begining of last year (Sep17)
to the end of last year (Sep18) was
(556125.796 + 575542.365 + 696268.844 + 834093.394 + 1259077.784) / 5 = ARS784221.6366 Mil. Total Assets at the begining of last year (Sep17) was ARS556,125.80 Mil. Long-Term Debt & Capital Lease Obligation was ARS726,485.86 Mil. Total Current Assets was ARS288,025.77 Mil. Total Current Liabilities was ARS135,530.72 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Celgene's current Net Income (TTM) was 265,613.09.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Celgene's return on assets of this year was 0.21095845. Celgene's return on assets of last year was 0.14633052.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Celgene's current Net Income (TTM) was 265,613.09. Celgene's current Cash Flow from Operations (TTM) was 364,330.33.
==> 364,330.33 > 265,613.09 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Celgene's gearing of this year was 0.62888589. Celgene's gearing of last year was 0.92637824.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Celgene's current ratio of this year was 2.8856059. Celgene's current ratio of last year was 2.1251697.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Celgene's number of shares in issue this year was 729.5. Celgene's number of shares in issue last year was 719.7.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Celgene's gross margin of this year was 0.96319676. Celgene's gross margin of last year was 0.96301276.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Celgene's asset turnover of this year was 0.60276297. Celgene's asset turnover of last year was 0.67635402.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
0
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Celgene has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Celgene (BUE:CELG) has a Piotroski F-Score of 8 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Celgene and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Celgene's Piotroski F-Score has ranged from 1.00 to 9.00.
Is Celgene's Piotroski F-Score too high?
Celgene's current Piotroski F-Score of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Celgene's value of 8 is 60% above this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Piotroski F-Score compare to GILD and BIIB?
Celgene's Piotroski F-Score of 8 can be compared against companies in the Drug Manufacturers industry. The industry median Piotroski F-Score is 5.00. Celgene's value of 8 is 60% above this benchmark. Historically, Celgene's own Piotroski F-Score has ranged from 1.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Celgene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current Piotroski F-Score is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Piotroski F-Score of 8. The current Piotroski F-Score is 8, which is 60% above median its 10-year median of 5.00 and 60% above the Drug Manufacturers industry median of 5.00. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Piotroski F-Score is 8 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 